Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases
|
摘要
Proteases, enzymes catalyzing the hydrolysis of peptide bonds, are present at high concentrations in the gastrointestinal tract. Besides their well-known role in the digestive process, they also function as signaling molecules through the activation of protease-activated receptors(PARs). Based on their chemical mechanism for catalysis, proteases can be classified into several classes: serine, cysteine, aspartic, metallo- and threonine proteases represent the mammalian protease families. In particular, the class of serine proteases will play a significant role in this review. In the last decades, proteases have been suggested to play a key role in the pathogenesis of visceral hypersensitivity, which is a major factor contributing to abdominal pain in patients with inflammatory bowel diseases and/or irritable bowel syndrome. So far, only a few preclinical animal studies have investigated the effect of protease inhibitors specifically on visceral sensitivity while their effect on inflammation is described in more detail. In our accompanying review we describe their effect on gastrointestinal permeability. On account of their promising results in the field of visceral hypersensitivity, further research is warranted. The aim of this review is to give an overview on the concept of visceral hypersensitivity as well as on the physiological and pathophysiological functions of proteases herein.
Proteases, enzymes catalyzing the hydrolysis of peptide bonds, are present at high concentrations in the gastrointestinal tract. Besides their well-known role in the digestive process, they also function as signaling molecules through the activation of protease-activated receptors(PARs). Based on their chemical mechanism for catalysis, proteases can be classified into several classes: serine, cysteine, aspartic, metallo- and threonine proteases represent the mammalian protease families. In particular, the class of serine proteases will play a significant role in this review. In the last decades, proteases have been suggested to play a key role in the pathogenesis of visceral hypersensitivity, which is a major factor contributing to abdominal pain in patients with inflammatory bowel diseases and/or irritable bowel syndrome. So far, only a few preclinical animal studies have investigated the effect of protease inhibitors specifically on visceral sensitivity while their effect on inflammation is described in more detail. In our accompanying review we describe their effect on gastrointestinal permeability. On account of their promising results in the field of visceral hypersensitivity, further research is warranted. The aim of this review is to give an overview on the concept of visceral hypersensitivity as well as on the physiological and pathophysiological functions of proteases herein.
Proteases, enzymes catalyzing the hydrolysis of peptide bonds, are present at high concentrations in the gastrointestinal tract. Besides their well-known role in the digestive process, they also function as signaling molecules through the activation of protease-activated receptors(PARs). Based on their chemical mechanism for catalysis, proteases can be classified into several classes: serine, cysteine, aspartic, metallo- and threonine proteases represent the mammalian protease families. In particular, the class of serine proteases will play a significant role in this review. In the last decades, proteases have been suggested to play a key role in the pathogenesis of visceral hypersensitivity, which is a major factor contributing to abdominal pain in patients with inflammatory bowel diseases and/or irritable bowel syndrome. So far, only a few preclinical animal studies have investigated the effect of protease inhibitors specifically on visceral sensitivity while their effect on inflammation is described in more detail. In our accompanying review we describe their effect on gastrointestinal permeability. On account of their promising results in the field of visceral hypersensitivity, further research is warranted. The aim of this review is to give an overview on the concept of visceral hypersensitivity as well as on the physiological and pathophysiological functions of proteases herein.
引文
1 Podolsky DK.Inflammatory bowel disease.N Engl J Med 2002;347:417-429[PMID:12167685 DOI:10.1056/NEJMra020831]
2 Chey WD,Kurlander J,Eswaran S.Irritable bowel syndrome:a clinical review.JAMA 2015;313:949-958[PMID:25734736 DOI:10.1001/jama.2015.0954]
3 Drossman DA.Functional Gastrointestinal Disorders:History,Pathophysiology,Clinical Features and Rome IV.Gastroenterology2016;Epub ahead of print[PMID:27144617 DOI:10.1053/j.gastro.2016.02.032]
4 Ananthakrishnan AN.Epidemiology and risk factors for IBD.Nat Rev Gastroenterol Hepatol 2015;12:205-217[PMID:25732745DOI:10.1038/nrgastro.2015.34]
5 Lovell RM,Ford AC.Global prevalence of and risk factors for irritable bowel syndrome:a meta-analysis.Clin Gastroenterol Hepatol 2012;10:712-721.e4[PMID:22426087 DOI:10.1016/j.cgh.2012.02.029]
6 Halpin SJ,Ford AC.Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease:systematic review and meta-analysis.Am J Gastroenterol 2012;107:1474-1482[PMID:22929759 DOI:10.1038/ajg.2012.260]
7 De Schepper HU,De Man JG,Moreels TG,Pelckmans PA,De Winter BY.Review article:gastrointestinal sensory and motor disturbances in inflammatory bowel disease-clinical relevance and pathophysiological mechanisms.Aliment Pharmacol Ther 2008;27:621-637[PMID:18221407 DOI:10.1111/j.1365-2036.2008.03624.x]
8 Hungin AP,Whorwell PJ,Tack J,Mearin F.The prevalence,patterns and impact of irritable bowel syndrome:an international survey of 40,000 subjects.Aliment Pharmacol Ther 2003;17:643-650[PMID:12641512]
9 Spiller R.Clinical update:irritable bowel syndrome.Lancet2007;369:1586-1588[PMID:17499587 DOI:10.1016/S0140-6736(07)60726-0]
10 Barbara G,Cremon C,De Giorgio R,Dothel G,Zecchi L,Bellacosa L,Carini G,Stanghellini V,Corinaldesi R.Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome.Curr Gastroenterol Rep 2011;13:308-315[PMID:21537962 DOI:10.1007/s11894-011-0195-7]
11 Blackshaw LA,Brookes SJ,Grundy D,Schemann M.Sensory transmission in the gastrointestinal tract.Neurogastroenterol M o t i l 2 0 0 7;1 9:1-1 9[P M I D:1 7 2 8 0 5 8 2 D O I:1 0.1111/j.1365-2982.2006.00871.x]
12 Anand P,Aziz Q,Willert R,van Oudenhove L.Peripheral and central mechanisms of visceral sensitization in man.Neurogastroenterol Motil 2007;19:29-46[PMID:17280584 DOI:10.1111/j.1365-2982.2006.00873.x]
13 Vermeulen W,De Man JG,Pelckmans PA,De Winter BY.Neuroanatomy of lower gastrointestinal pain disorders.World J Gastroenterol 2014;20:1005-1020[PMID:24574773 DOI:10.3748/wjg.v20.i4.1005]
14 Marshall JK,Thabane M,Garg AX,Clark WF,Moayyedi P,Collins SM.Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery.Gut 2010;59:605-611[PMID:20427395 DOI:10.1136/gut.2009.202234]
15 Van Spaendonk H,Ceuleers H,Witters L,Patteet E,Joossens J,Augustyns K,Lambeir AM,De Meester I,De Man JG,De Winter BY.Gastrointestinal permeability:The role of proteases.World JGastroenterol 2016;in Press
16 Sikandar S,Dickenson AH.Visceral pain:the ins and outs,the ups and downs.Curr Opin Support Palliat Care 2012;6:17-26[PMID:22246042 DOI:10.1097/SPC.0b013e32834f6ec9]
17 Akbar A,Walters JR,Ghosh S.Review article:visceral hypersensitivity in irritable bowel syndrome:molecular mechanisms and therapeutic agents.Aliment Pharmacol Ther 2009;30:423-435[PMID:19493256 DOI:10.1111/j.1365-2036.2009.04056.x]
18 Camilleri M,Coulie B,Tack JF.Visceral hypersensitivity:facts,speculations,and challenges.Gut 2001;48:125-131[PMID:11115834]
19 Keszthelyi D,Troost FJ,Masclee AA.Irritable bowel syndrome:methods,mechanisms,and pathophysiology.Methods to assess visceral hypersensitivity in irritable bowel syndrome.Am JPhysiol Gastrointest Liver Physiol 2012;303:G141-G154[PMID:22595988 DOI:10.1152/ajpgi.00060.2012]
20 de Carvalho Rocha HA,Dantas BP,Rolim TL,Costa BA,de Medeiros AC.Main ion channels and receptors associated with visceral hypersensitivity in irritable bowel syndrome.Ann Gastroenterol 2014;27:200-206[PMID:24976114]
21 De Winter BY,van den Wijngaard RM,de Jonge WJ.Intestinal mast cells in gut inflammation and motility disturbances.Biochim Biophys Acta 2012;1822:66-73[PMID:21497195 DOI:10.1016/j.bbadis.2011.03.016]
22 Barbara G,Stanghellini V,De Giorgio R,Cremon C,Cottrell GS,Santini D,Pasquinelli G,Morselli-Labate AM,Grady EF,Bunnett NW,Collins SM,Corinaldesi R.Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.Gastroenterology 2004;126:693-702[PMID:14988823]
23 Deiteren A,De Man JG,Ruyssers NE,Moreels TG,Pelckmans PA,De Winter BY.Histamine H4 and H1 receptors contribute to postinflammatory visceral hypersensitivity.Gut 2014;63:1873-1882[PMID:24561612 DOI:10.1136/gutjnl-2013-305870]
24 Wouters MM,Balemans D,Van Wanrooy S,Dooley J,CibertGoton V,Alpizar YA,Valdez-Morales EE,Nasser Y,Van Veldhoven PP,Vanbrabant W,Van der Merwe S,Mols R,Ghesquière B,Cirillo C,Kortekaas I,Carmeliet P,Peetermans WE,Vermeire S,Rutgeerts P,Augustijns P,Hellings PW,Belmans A,Vanner S,Bulmer DC,Talavera K,Vanden Berghe P,Liston A,Boeckxstaens GE.Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.Gastroenterology 2016;150:875-87.e9[PMID:26752109 DOI:10.1053/j.gastro.2015.12.034]
25 Zhang L,Song J,Hou X.Mast Cells and Irritable Bowel Syndrome:From the Bench to the Bedside.J Neurogastroenterol Motil2016;22:181-192[PMID:26755686 DOI:10.5056/jnm15137]
26 Vergnolle N.Modulation of visceral pain and inflammation by protease-activated receptors.Br J Pharmacol 2004;141:1264-1274[PMID:15051630 DOI:10.1038/sj.bjp.0705750]
27 Antalis TM,Shea-Donohue T,Vogel SN,Sears C,Fasano A.Mechanisms of disease:protease functions in intestinal mucosal pathobiology.Nat Clin Pract Gastroenterol Hepatol 2007;4:393-402[PMID:17607295 DOI:10.1038/ncpgasthep0846]
28 Rao MB,Tanksale AM,Ghatge MS,Deshpande VV.Molecular and biotechnological aspects of microbial proteases.Microbiol Mol Biol Rev 1998;62:597-635[PMID:9729602]
29 Hooper NM.Proteases:a primer.Essays Biochem 2002;38:1-8[PMID:12463157]
30 Barrett AJ.The many forms and functions of cellular proteinases.Fed Proc 1980;39:9-14[PMID:6985872]
31 Barrett AJ.Classification of peptidases.Methods Enzymol 1994;244:1-15[PMID:7845199]
32 Powers JC,Odake S,Oleksyszyn J,Hori H,Ueda T,Boduszek B,Kam C.Proteases--structures,mechanism and inhibitors.Agents Actions Suppl 1993;42:3-18[PMID:8356929]
33 Rawlings ND,Barrett AJ,Bateman A.Asparagine peptide lyases:a seventh catalytic type of proteolytic enzymes.J Biol Chem2011;286:38321-38328[PMID:21832066 DOI:10.1074/jbc.M111.260026]
34 Turk B.Targeting proteases:successes,failures and future prospects.Nat Rev Drug Discov 2006;5:785-799[PMID:16955069 DOI:10.1038/nrd2092]
35 Vergnolle N.Protease inhibition as new therapeutic strategy for GI diseases.Gut 2016;65:1215-1224[PMID:27196587 DOI:10.1136/gutjnl-2015-309147]
36 Cenac N,Garcia-Villar R,Ferrier L,Larauche M,Vergnolle N,Bunnett NW,Coelho AM,Fioramonti J,Bueno L.Proteinaseactivated receptor-2-induced colonic inflammation in mice:possible involvement of afferent neurons,nitric oxide,and paracellular permeability.J Immunol 2003;170:4296-4300[PMID:12682265]
37 Cenac N.Protease-activated receptors as therapeutic targets in visceral pain.Curr Neuropharmacol 2013;11:598-605[PMID:24396336 DOI:10.2174/1570159X113119990039]
38 Vergnolle N.Clinical relevance of proteinase activated receptors(pars)in the gut.Gut 2005;54:867-874[PMID:15888798 DOI:10.1136/gut.2004.048876]
39 Zhao P,Metcalf M,Bunnett NW.Biased signaling of proteaseactivated receptors.Front Endocrinol(Lausanne)2014;5:67[PMID:24860547 DOI:10.3389/fendo.2014.00067]
40 Hollenberg MD,Compton SJ.International Union of Pharmacology.XXVIII.Proteinase-activated receptors.Pharmacol Rev2002;54:203-217[PMID:12037136]
41 Cenac N,Andrews CN,Holzhausen M,Chapman K,Cottrell G,Andrade-Gordon P,Steinhoff M,Barbara G,Beck P,Bunnett NW,Sharkey KA,Ferraz JG,Shaffer E,Vergnolle N.Role for protease activity in visceral pain in irritable bowel syndrome.J Clin Invest2007;117:636-647[PMID:17304351 DOI:10.1172/JCI29255]
42 Zhao JH,Dong L,Shi HT,Wang ZY,Shi HY,Ding H.The expression of protease-activated receptor 2 and 4 in the colon of irritable bowel syndrome patients.Dig Dis Sci 2012;57:58-64[PMID:21800160 DOI:10.1007/s10620-011-1827-3]
43 Buhner S,Li Q,Vignali S,Barbara G,De Giorgio R,Stanghellini V,Cremon C,Zeller F,Langer R,Daniel H,Michel K,Schemann M.Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome.Gastroenterology 2009;137:1425-1434[PMID:19596012 DOI:10.1053/j.gastro.2009.07.005]
44 Liang WJ,Zhang G,Luo HS,Liang LX,Huang D,Zhang FC.Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome.Gut Liver 2016;10:382-390[PMID:26446924 DOI:10.5009/gnl14319]
45 Bian ZX,Li Z,Huang ZX,Zhang M,Chen HL,Xu HX,Sung JJ.Unbalanced expression of protease-activated receptors-1 and-2 in the colon of diarrhea-predominant irritable bowel syndrome patients.J Gastroenterol 2009;44:666-674[PMID:19430717DOI:10.1007/s00535-009-0058-2]
46 Swan C,Duroudier NP,Campbell E,Zaitoun A,Hastings M,Dukes GE,Cox J,Kelly FM,Wilde J,Lennon MG,Neal KR,Whorwell PJ,Hall IP,Spiller RC.Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome(IBS):association with TNFSF15 and TNFα.Gut 2013;62:985-994[PMID:22684480 DOI:10.1136/gutjnl-2011-301213]
47 Lettesj?H,Hansson T,Peterson C,Ung KA,Ringstr?m G,Abrahamsson H,Simrén M.Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis.Scand J Gastroenterol 2006;41:54-59[PMID:16373277DOI:10.1080/00365520510023909]
48 Róka R,Rosztóczy A,Leveque M,Izbéki F,Nagy F,Molnár T,Lonovics J,Garcia-Villar R,Fioramonti J,Wittmann T,Bueno L.A pilot study of fecal serine-protease activity:a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome.Clin Gastroenterol Hepatol 2007;5:550-555[PMID:17336590 DOI:10.1016/j.cgh.2006.12.004]
49 Annaházi A,Gecse K,Dabek M,Ait-Belgnaoui A,Rosztóczy A,Róka R,Molnár T,Theodorou V,Wittmann T,Bueno L,Eutamene H.Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice.Pain 2009;144:209-217[PMID:19450926 DOI:10.1016/j.pain.2009.04.017]
50 Gecse K,Róka R,Ferrier L,Leveque M,Eutamene H,Cartier C,Ait-Belgnaoui A,Rosztóczy A,Izbéki F,Fioramonti J,Wittmann T,Bueno L.Increased faecal serine protease activity in diarrhoeic IBSpatients:a colonic lumenal factor impairing colonic permeability and sensitivity.Gut 2008;57:591-599[PMID:18194983 DOI:10.1136/gut.2007.140210]
51 Ibeakanma C,Ochoa-Cortes F,Miranda-Morales M,McD onald T,Spreadbury I,Cenac N,Cattaruzza F,Hurlbut D,Vanner S,Bunnett N,Vergnolle N,Vanner S.Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome.Gastroenterology 2011;141:2098-2108.e5[PMID:21856270 DOI:10.1053/j.gastro.2011.08.006]
52 Tooth D,Garsed K,Singh G,Marciani L,Lam C,Fordham I,Fields A,Banwait R,Lingaya M,Layfield R,Hastings M,Whorwell P,Spiller R.Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea:origin and effect of gut transit.Gut 2014;63:753-760[PMID:23911555 DOI:10.1136/gutjnl-2012-304042]
53 Annaházi A,Ferrier L,Bézirard V,Lévêque M,Eutamène H,AitBelgnaoui A,Co?ffier M,DucrottéP,Róka R,Inczefi O,Gecse K,Rosztóczy A,Molnár T,Ringel-Kulka T,Ringel Y,Piche T,Theodorou V,Wittmann T,Bueno L.Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS.Am JGastroenterol 2013;108:1322-1331[PMID:23711626 DOI:10.1038/ajg.2013.152]
54 Edgington-Mitchell LE.Pathophysiological roles of proteases in gastrointestinal disease.Am J Physiol Gastrointest Liver Physiol 2016;310:G234-G239[PMID:26702140 DOI:10.1152/ajpgi.00393.2015]
55 Kawao N,Ikeda H,Kitano T,Kuroda R,Sekiguchi F,Kataoka K,Kamanaka Y,Kawabata A.Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and2.J Pharmacol Sci 2004;94:277-285[PMID:15037813]
56 Kawabata A,Kawao N,Kuroda R,Tanaka A,Shimada C.The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats.Peptides 2002;23:1181-1183[PMID:12126749]
57 AugéC,Balz-Hara D,Steinhoff M,Vergnolle N,Cenac N.Proteaseactivated receptor-4(PAR 4):a role as inhibitor of visceral pain and hypersensitivity.Neurogastroenterol Motil 2009;21:1189-e107[PMID:19413681 DOI:10.1111/j.1365-2982.2009.01310.x]
58 Han W,Wang Z,Lu X,Guo C.Protease activated receptor 4status of mast cells in post infectious irritable bowel syndrome.Neurogastroenterol Motil 2012;24:113-19,e82[PMID:22151913DOI:10.1111/j.1365-2982.2011.01841.x]
59 Kawabata A,Kawao N,Kuroda R,Tanaka A,Itoh H,Nishikawa H.Peripheral PAR-2 triggers thermal hyperalgesia and nociceptive responses in rats.Neuroreport 2001;12:715-719[PMID:11277570]
60 Coelho AM,Vergnolle N,Guiard B,Fioramonti J,Bueno L.Proteinases and proteinase-activated receptor 2:a possible role to promote visceral hyperalgesia in rats.Gastroenterology 2002;122:1035-1047[PMID:11910355]
61 Reed DE,Barajas-Lopez C,Cottrell G,Velazquez-Rocha S,Dery O,Grady EF,Bunnett NW,Vanner SJ.Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of guineapig submucosal neurons.J Physiol 2003;547:531-542[PMID:12562962 DOI:10.1113/jphysiol.2002.032011]
62 Vergnolle N,Bunnett NW,Sharkey KA,Brussee V,Compton SJ,Grady EF,Cirino G,Gerard N,Basbaum AI,Andrade-Gordon P,Hollenberg MD,Wallace JL.Proteinase-activated receptor-2 and hyperalgesia:A novel pain pathway.Nat Med 2001;7:821-826[PMID:11433347 DOI:10.1038/89945]
63 Kawabata A,Kawao N,Kitano T,Matsunami M,Satoh R,Ishiki T,Masuko T,Kanke T,Saito N.Colonic hyperalgesia triggered by proteinase-activated receptor-2 in mice:involvement of endogenous bradykinin.Neurosci Lett 2006;402:167-172[PMID:16644120DOI:10.1016/j.neulet.2006.03.074]
64 Valdez-Morales EE,Overington J,Guerrero-Alba R,Ochoa-Cortes F,Ibeakanma CO,Spreadbury I,Bunnett NW,Beyak M,Vanner SJ.Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients:a role for PAR2.Am J Gastroenterol 2013;108:1634-1643[PMID:23958521 DOI:10.1038/ajg.2013.241]
65 Wang P,Chen FX,Du C,Li CQ,Yu YB,Zuo XL,Li YQ.Increased production of BDNF in colonic epithelial cells induced by fecal supernatants from diarrheic IBS patients.Sci Rep 2015;5:10121[PMID:25998025 DOI:10.1038/srep10121]
66 Ceuleers H,Segaert E,Heirbaut J,Hanning N,Francque SM,Joossens J,De Meester I,De Man J,De Winter BY.Su1937Two Serine Protease Inhibitors,Nafamostat Mesylate and the Newly Developed SPIx,Decrease Post-Inflammatory Visceral Hypersensitivity in Rats.Gastroenterology 2016;150:S593-S4[DOI:10.1016/S0016-5085(16)32036-4]
67 Ceuleers H,De Man JG,Deiteren A,De Schepper H,Joossens J,Francque S.The effect of a potent tryptase inhibitor and a new serine protease inhibitor on visceral pain in a rat model of acute colitis.Friday,5 June 2015 08:30-10:00 Hall B2 FP-01 Sensory mechanisms.Neurogastroenterol Motility 2015;27:22-25[DOI:10.1111/nmo.12597]
68 Zhao J,Wang J,Dong L,Shi H,Wang Z,Ding H,Shi H,Lu X.A protease inhibitor against acute stress-induced visceral hypersensitivity and paracellular permeability in rats.Eur JPharmacol 2011;654:289-294[PMID:21237151 DOI:10.1016/j.ejphar.2010.12.032]
69 Zhao J,Wang Z,Zou B,Song Y,Dong L.[Camostat mesilate,a protease inhibitor,inhibits visceral sensitivity and spinal c-fos expression in rats with acute restraint stress].Nan Fang Yi Ke Da Xue Xue Bao 2014;34:1546-1550[PMID:25345960]
70 Moussa L,Bézirard V,Salvador-Cartier C,BacquiéV,Lencina C,Lévêque M,Braniste V,Ménard S,Théodorou V,Houdeau E.A low dose of fermented soy germ alleviates gut barrier injury,hyperalgesia and faecal protease activity in a rat model of inflammatory bowel disease.PLo S One 2012;7:e49547[PMID:23166707 DOI:10.1371/journal.pone.0049547]
71 Moussa L,Bézirard V,Salvador-Cartier C,BacquiéV,Houdeau E,Théodorou V.A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats.Clin Nutr 2013;32:51-58[PMID:22727545 DOI:10.1016/j.clnu.2012.05.021]
72 Bermúdez-Humarán LG,Motta JP,Aubry C,Kharrat P,RousMartin L,Sallenave JM,Deraison C,Vergnolle N,Langella P.Serine protease inhibitors protect better than IL-10 and TGF-βantiinflammatory cytokines against mouse colitis when delivered by recombinant lactococci.Microb Cell Fact 2015;14:26[PMID:25889561 DOI:10.1186/s12934-015-0198-4]
73 Mavrakanas TA,Chatzizisis YS.Bivalirudin in stable angina and acute coronary syndromes.Pharmacol Ther 2015;152:1-10[PMID:25857452 DOI:10.1016/j.pharmthera.2015.04.003]
74 Reddy P,Giugliano RP.The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.J Cardiovasc Pharmacol Ther 2014;19:526-532[PMID:24659084 DOI:10.1177/1074248414525505]
75 Mc Cormack PL.Edoxaban:a review in nonvalvular atrial fibrillation.Am J Cardiovasc Drugs 2015;15:351-361[PMID:26369340 DOI:10.1007/s40256-015-0148-x]
76 Fanola CL.Current and emerging strategies in the management of venous thromboembolism:benefit-risk assessment of dabigatran.Vasc Health Risk Manag 2015;11:271-282[PMID:26064057DOI:10.2147/VHRM.S62595]
77 Fujii K,Kanno Y,Konishi K,Ohgou N.A specific thrombin inhibitor,argatroban,alleviates herpes zoster-associated pain.JDermatol 2001;28:200-207[PMID:11449671]
78 Armstrong WB,Taylor TH,Kennedy AR,Melrose RJ,Messadi DV,Gu M,Le AD,Perloff M,Civantos F,Goodwin WJ,Wirth LJ,Kerr AR,Meyskens FL.Bowman birk inhibitor concentrate and oral leukoplakia:a randomized phase IIb trial.Cancer Prev Res(Phila)2013;6:410-418[PMID:23639862 DOI:10.1158/1940-6207.CAPR-13-0004]
79 Scully M,Gates C,Neave L.How we manage patients with heparin induced thrombocytopenia.Br J Haematol 2016;174:9-15[PMID:27097741 DOI:10.1111/bjh.14102]
80 Heinemann V,Ebert MP,Laubender RP,Bevan P,Mala C,Boeck S.Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat(WX-671)in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable,locally advanced pancreatic cancer.Br J Cancer 2013;108:766-770[PMID:23412098 DOI:10.1038/bjc.2013.62]
81 Uwagawa T,Misawa T,Tsutsui N,Ito R,Gocho T,Hirohara S,Sadaoka S,Yanaga K.Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.Am J Clin Oncol 2013;36:44-48[PMID:22157216 DOI:10.1097/COC.0b013e31823a53b2]
82 Bao P,Zhao W,Li Y,Liu Y,Zhou Y,Liu C.Protective effect of ulinastatin in patients with non-small cell lung cancer after radiation therapy:a randomized,placebo-controlled study.Med Oncol 2015;32:405[PMID:25502081 DOI:10.1007/s12032-014-0405-x]
83 Narra K,Mullins SR,Lee HO,Strzemkowski-Brun B,Magalong K,Christiansen VJ,McK ee PA,Egleston B,Cohen SJ,Weiner LM,Meropol NJ,Cheng JD.Phase II trial of single agent Val-boroP ro(Talabostat)inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.Cancer Biol Ther 2007;6:1691-1699[PMID:18032930]
84 Zhang L,Wang N,Zhou S,Ye W,Yao Q,Jing G,Zhang M.Preventive effect of ulinastatin on postoperative complications,immunosuppression,and recurrence in esophagectomy patients.World J Surg Oncol 2013;11:84[PMID:23575450 DOI:10.1186/1477-7819-11-84]
85 Krishna MT,Chauhan A,Little L,Sampson K,Hawksworth R,Mant T,Djukanovic R,Lee T,Holgate S.Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma.J Allergy Clin Immunol 2001;107:1039-1045[PMID:11398082 DOI:10.1067/mai.2001.115631]
86 Strange C,Beiko T.Treatment of Alpha-1 Antitrypsin Deficiency.Semin Respir Crit Care Med 2015;36:470-477[PMID:26238635DOI:10.1055/s-0035-1555608]
87 Twigg MS,Brockbank S,Lowry P,Fitz Gerald SP,Taggart C,Weldon S.The Role of Serine Proteases and Antiproteases in the Cystic Fibrosis Lung.Mediators Inflamm 2015;2015:293053[PMID:26185359 DOI:10.1155/2015/293053]
88 Thomas MC,Paldánius PM,Ayyagari R,Ong SH,Groop PH.Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.Diabetes Ther 2016;7:439-454[PMID:27502495 DOI:10.1007/s13300-016-0189-4]
89 Royston D.The current place of aprotinin in the management of bleeding.Anaesthesia 2015;70 Suppl 1:46-9,e17[PMID:25440394 DOI:10.1111/anae.12907]
90 Ono S,Aosasa S,Mochizuki H.Effects of a protease inhibitor on reduction of surgical stress in esophagectomy.Am J Surg 1999;177:78-82[PMID:10037314]
91 Inagaki H,Nonami T,Kurokawa T,Takeuchi Y,Okuda N,Nakao A,Sakamoto J.Effects of nafamostat mesilate,a synthetic protease inhibitor,on immunity and coagulation after hepatic resection.Hepatogastroenterology 1999;46:3223-3228[PMID:10626190]
92 Ito H,Nakayama H,Yokose T,Yamada K.Prophylaxis for acute exacerbation of interstitial pneumonia after lung resection.Asian Cardiovasc Thorac Ann 2014;22:948-954[PMID:24585320 DOI:10.1177/0218492314526187]
93 Joossens J,Ali OM,El-Sayed I,Surpateanu G,Van der Veken P,Lambeir AM,Setyono-Han B,Foekens JA,Schneider A,Schmalix W,Haemers A,Augustyns K.Small,potent,and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties.J Med Chem 2007;50:6638-6646[PMID:18052026 DOI:10.1021/jm700962j]
2 Chey WD,Kurlander J,Eswaran S.Irritable bowel syndrome:a clinical review.JAMA 2015;313:949-958[PMID:25734736 DOI:10.1001/jama.2015.0954]
3 Drossman DA.Functional Gastrointestinal Disorders:History,Pathophysiology,Clinical Features and Rome IV.Gastroenterology2016;Epub ahead of print[PMID:27144617 DOI:10.1053/j.gastro.2016.02.032]
4 Ananthakrishnan AN.Epidemiology and risk factors for IBD.Nat Rev Gastroenterol Hepatol 2015;12:205-217[PMID:25732745DOI:10.1038/nrgastro.2015.34]
5 Lovell RM,Ford AC.Global prevalence of and risk factors for irritable bowel syndrome:a meta-analysis.Clin Gastroenterol Hepatol 2012;10:712-721.e4[PMID:22426087 DOI:10.1016/j.cgh.2012.02.029]
6 Halpin SJ,Ford AC.Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease:systematic review and meta-analysis.Am J Gastroenterol 2012;107:1474-1482[PMID:22929759 DOI:10.1038/ajg.2012.260]
7 De Schepper HU,De Man JG,Moreels TG,Pelckmans PA,De Winter BY.Review article:gastrointestinal sensory and motor disturbances in inflammatory bowel disease-clinical relevance and pathophysiological mechanisms.Aliment Pharmacol Ther 2008;27:621-637[PMID:18221407 DOI:10.1111/j.1365-2036.2008.03624.x]
8 Hungin AP,Whorwell PJ,Tack J,Mearin F.The prevalence,patterns and impact of irritable bowel syndrome:an international survey of 40,000 subjects.Aliment Pharmacol Ther 2003;17:643-650[PMID:12641512]
9 Spiller R.Clinical update:irritable bowel syndrome.Lancet2007;369:1586-1588[PMID:17499587 DOI:10.1016/S0140-6736(07)60726-0]
10 Barbara G,Cremon C,De Giorgio R,Dothel G,Zecchi L,Bellacosa L,Carini G,Stanghellini V,Corinaldesi R.Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome.Curr Gastroenterol Rep 2011;13:308-315[PMID:21537962 DOI:10.1007/s11894-011-0195-7]
11 Blackshaw LA,Brookes SJ,Grundy D,Schemann M.Sensory transmission in the gastrointestinal tract.Neurogastroenterol M o t i l 2 0 0 7;1 9:1-1 9[P M I D:1 7 2 8 0 5 8 2 D O I:1 0.1111/j.1365-2982.2006.00871.x]
12 Anand P,Aziz Q,Willert R,van Oudenhove L.Peripheral and central mechanisms of visceral sensitization in man.Neurogastroenterol Motil 2007;19:29-46[PMID:17280584 DOI:10.1111/j.1365-2982.2006.00873.x]
13 Vermeulen W,De Man JG,Pelckmans PA,De Winter BY.Neuroanatomy of lower gastrointestinal pain disorders.World J Gastroenterol 2014;20:1005-1020[PMID:24574773 DOI:10.3748/wjg.v20.i4.1005]
14 Marshall JK,Thabane M,Garg AX,Clark WF,Moayyedi P,Collins SM.Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery.Gut 2010;59:605-611[PMID:20427395 DOI:10.1136/gut.2009.202234]
15 Van Spaendonk H,Ceuleers H,Witters L,Patteet E,Joossens J,Augustyns K,Lambeir AM,De Meester I,De Man JG,De Winter BY.Gastrointestinal permeability:The role of proteases.World JGastroenterol 2016;in Press
16 Sikandar S,Dickenson AH.Visceral pain:the ins and outs,the ups and downs.Curr Opin Support Palliat Care 2012;6:17-26[PMID:22246042 DOI:10.1097/SPC.0b013e32834f6ec9]
17 Akbar A,Walters JR,Ghosh S.Review article:visceral hypersensitivity in irritable bowel syndrome:molecular mechanisms and therapeutic agents.Aliment Pharmacol Ther 2009;30:423-435[PMID:19493256 DOI:10.1111/j.1365-2036.2009.04056.x]
18 Camilleri M,Coulie B,Tack JF.Visceral hypersensitivity:facts,speculations,and challenges.Gut 2001;48:125-131[PMID:11115834]
19 Keszthelyi D,Troost FJ,Masclee AA.Irritable bowel syndrome:methods,mechanisms,and pathophysiology.Methods to assess visceral hypersensitivity in irritable bowel syndrome.Am JPhysiol Gastrointest Liver Physiol 2012;303:G141-G154[PMID:22595988 DOI:10.1152/ajpgi.00060.2012]
20 de Carvalho Rocha HA,Dantas BP,Rolim TL,Costa BA,de Medeiros AC.Main ion channels and receptors associated with visceral hypersensitivity in irritable bowel syndrome.Ann Gastroenterol 2014;27:200-206[PMID:24976114]
21 De Winter BY,van den Wijngaard RM,de Jonge WJ.Intestinal mast cells in gut inflammation and motility disturbances.Biochim Biophys Acta 2012;1822:66-73[PMID:21497195 DOI:10.1016/j.bbadis.2011.03.016]
22 Barbara G,Stanghellini V,De Giorgio R,Cremon C,Cottrell GS,Santini D,Pasquinelli G,Morselli-Labate AM,Grady EF,Bunnett NW,Collins SM,Corinaldesi R.Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.Gastroenterology 2004;126:693-702[PMID:14988823]
23 Deiteren A,De Man JG,Ruyssers NE,Moreels TG,Pelckmans PA,De Winter BY.Histamine H4 and H1 receptors contribute to postinflammatory visceral hypersensitivity.Gut 2014;63:1873-1882[PMID:24561612 DOI:10.1136/gutjnl-2013-305870]
24 Wouters MM,Balemans D,Van Wanrooy S,Dooley J,CibertGoton V,Alpizar YA,Valdez-Morales EE,Nasser Y,Van Veldhoven PP,Vanbrabant W,Van der Merwe S,Mols R,Ghesquière B,Cirillo C,Kortekaas I,Carmeliet P,Peetermans WE,Vermeire S,Rutgeerts P,Augustijns P,Hellings PW,Belmans A,Vanner S,Bulmer DC,Talavera K,Vanden Berghe P,Liston A,Boeckxstaens GE.Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.Gastroenterology 2016;150:875-87.e9[PMID:26752109 DOI:10.1053/j.gastro.2015.12.034]
25 Zhang L,Song J,Hou X.Mast Cells and Irritable Bowel Syndrome:From the Bench to the Bedside.J Neurogastroenterol Motil2016;22:181-192[PMID:26755686 DOI:10.5056/jnm15137]
26 Vergnolle N.Modulation of visceral pain and inflammation by protease-activated receptors.Br J Pharmacol 2004;141:1264-1274[PMID:15051630 DOI:10.1038/sj.bjp.0705750]
27 Antalis TM,Shea-Donohue T,Vogel SN,Sears C,Fasano A.Mechanisms of disease:protease functions in intestinal mucosal pathobiology.Nat Clin Pract Gastroenterol Hepatol 2007;4:393-402[PMID:17607295 DOI:10.1038/ncpgasthep0846]
28 Rao MB,Tanksale AM,Ghatge MS,Deshpande VV.Molecular and biotechnological aspects of microbial proteases.Microbiol Mol Biol Rev 1998;62:597-635[PMID:9729602]
29 Hooper NM.Proteases:a primer.Essays Biochem 2002;38:1-8[PMID:12463157]
30 Barrett AJ.The many forms and functions of cellular proteinases.Fed Proc 1980;39:9-14[PMID:6985872]
31 Barrett AJ.Classification of peptidases.Methods Enzymol 1994;244:1-15[PMID:7845199]
32 Powers JC,Odake S,Oleksyszyn J,Hori H,Ueda T,Boduszek B,Kam C.Proteases--structures,mechanism and inhibitors.Agents Actions Suppl 1993;42:3-18[PMID:8356929]
33 Rawlings ND,Barrett AJ,Bateman A.Asparagine peptide lyases:a seventh catalytic type of proteolytic enzymes.J Biol Chem2011;286:38321-38328[PMID:21832066 DOI:10.1074/jbc.M111.260026]
34 Turk B.Targeting proteases:successes,failures and future prospects.Nat Rev Drug Discov 2006;5:785-799[PMID:16955069 DOI:10.1038/nrd2092]
35 Vergnolle N.Protease inhibition as new therapeutic strategy for GI diseases.Gut 2016;65:1215-1224[PMID:27196587 DOI:10.1136/gutjnl-2015-309147]
36 Cenac N,Garcia-Villar R,Ferrier L,Larauche M,Vergnolle N,Bunnett NW,Coelho AM,Fioramonti J,Bueno L.Proteinaseactivated receptor-2-induced colonic inflammation in mice:possible involvement of afferent neurons,nitric oxide,and paracellular permeability.J Immunol 2003;170:4296-4300[PMID:12682265]
37 Cenac N.Protease-activated receptors as therapeutic targets in visceral pain.Curr Neuropharmacol 2013;11:598-605[PMID:24396336 DOI:10.2174/1570159X113119990039]
38 Vergnolle N.Clinical relevance of proteinase activated receptors(pars)in the gut.Gut 2005;54:867-874[PMID:15888798 DOI:10.1136/gut.2004.048876]
39 Zhao P,Metcalf M,Bunnett NW.Biased signaling of proteaseactivated receptors.Front Endocrinol(Lausanne)2014;5:67[PMID:24860547 DOI:10.3389/fendo.2014.00067]
40 Hollenberg MD,Compton SJ.International Union of Pharmacology.XXVIII.Proteinase-activated receptors.Pharmacol Rev2002;54:203-217[PMID:12037136]
41 Cenac N,Andrews CN,Holzhausen M,Chapman K,Cottrell G,Andrade-Gordon P,Steinhoff M,Barbara G,Beck P,Bunnett NW,Sharkey KA,Ferraz JG,Shaffer E,Vergnolle N.Role for protease activity in visceral pain in irritable bowel syndrome.J Clin Invest2007;117:636-647[PMID:17304351 DOI:10.1172/JCI29255]
42 Zhao JH,Dong L,Shi HT,Wang ZY,Shi HY,Ding H.The expression of protease-activated receptor 2 and 4 in the colon of irritable bowel syndrome patients.Dig Dis Sci 2012;57:58-64[PMID:21800160 DOI:10.1007/s10620-011-1827-3]
43 Buhner S,Li Q,Vignali S,Barbara G,De Giorgio R,Stanghellini V,Cremon C,Zeller F,Langer R,Daniel H,Michel K,Schemann M.Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome.Gastroenterology 2009;137:1425-1434[PMID:19596012 DOI:10.1053/j.gastro.2009.07.005]
44 Liang WJ,Zhang G,Luo HS,Liang LX,Huang D,Zhang FC.Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome.Gut Liver 2016;10:382-390[PMID:26446924 DOI:10.5009/gnl14319]
45 Bian ZX,Li Z,Huang ZX,Zhang M,Chen HL,Xu HX,Sung JJ.Unbalanced expression of protease-activated receptors-1 and-2 in the colon of diarrhea-predominant irritable bowel syndrome patients.J Gastroenterol 2009;44:666-674[PMID:19430717DOI:10.1007/s00535-009-0058-2]
46 Swan C,Duroudier NP,Campbell E,Zaitoun A,Hastings M,Dukes GE,Cox J,Kelly FM,Wilde J,Lennon MG,Neal KR,Whorwell PJ,Hall IP,Spiller RC.Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome(IBS):association with TNFSF15 and TNFα.Gut 2013;62:985-994[PMID:22684480 DOI:10.1136/gutjnl-2011-301213]
47 Lettesj?H,Hansson T,Peterson C,Ung KA,Ringstr?m G,Abrahamsson H,Simrén M.Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis.Scand J Gastroenterol 2006;41:54-59[PMID:16373277DOI:10.1080/00365520510023909]
48 Róka R,Rosztóczy A,Leveque M,Izbéki F,Nagy F,Molnár T,Lonovics J,Garcia-Villar R,Fioramonti J,Wittmann T,Bueno L.A pilot study of fecal serine-protease activity:a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome.Clin Gastroenterol Hepatol 2007;5:550-555[PMID:17336590 DOI:10.1016/j.cgh.2006.12.004]
49 Annaházi A,Gecse K,Dabek M,Ait-Belgnaoui A,Rosztóczy A,Róka R,Molnár T,Theodorou V,Wittmann T,Bueno L,Eutamene H.Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice.Pain 2009;144:209-217[PMID:19450926 DOI:10.1016/j.pain.2009.04.017]
50 Gecse K,Róka R,Ferrier L,Leveque M,Eutamene H,Cartier C,Ait-Belgnaoui A,Rosztóczy A,Izbéki F,Fioramonti J,Wittmann T,Bueno L.Increased faecal serine protease activity in diarrhoeic IBSpatients:a colonic lumenal factor impairing colonic permeability and sensitivity.Gut 2008;57:591-599[PMID:18194983 DOI:10.1136/gut.2007.140210]
51 Ibeakanma C,Ochoa-Cortes F,Miranda-Morales M,McD onald T,Spreadbury I,Cenac N,Cattaruzza F,Hurlbut D,Vanner S,Bunnett N,Vergnolle N,Vanner S.Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome.Gastroenterology 2011;141:2098-2108.e5[PMID:21856270 DOI:10.1053/j.gastro.2011.08.006]
52 Tooth D,Garsed K,Singh G,Marciani L,Lam C,Fordham I,Fields A,Banwait R,Lingaya M,Layfield R,Hastings M,Whorwell P,Spiller R.Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea:origin and effect of gut transit.Gut 2014;63:753-760[PMID:23911555 DOI:10.1136/gutjnl-2012-304042]
53 Annaházi A,Ferrier L,Bézirard V,Lévêque M,Eutamène H,AitBelgnaoui A,Co?ffier M,DucrottéP,Róka R,Inczefi O,Gecse K,Rosztóczy A,Molnár T,Ringel-Kulka T,Ringel Y,Piche T,Theodorou V,Wittmann T,Bueno L.Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS.Am JGastroenterol 2013;108:1322-1331[PMID:23711626 DOI:10.1038/ajg.2013.152]
54 Edgington-Mitchell LE.Pathophysiological roles of proteases in gastrointestinal disease.Am J Physiol Gastrointest Liver Physiol 2016;310:G234-G239[PMID:26702140 DOI:10.1152/ajpgi.00393.2015]
55 Kawao N,Ikeda H,Kitano T,Kuroda R,Sekiguchi F,Kataoka K,Kamanaka Y,Kawabata A.Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and2.J Pharmacol Sci 2004;94:277-285[PMID:15037813]
56 Kawabata A,Kawao N,Kuroda R,Tanaka A,Shimada C.The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats.Peptides 2002;23:1181-1183[PMID:12126749]
57 AugéC,Balz-Hara D,Steinhoff M,Vergnolle N,Cenac N.Proteaseactivated receptor-4(PAR 4):a role as inhibitor of visceral pain and hypersensitivity.Neurogastroenterol Motil 2009;21:1189-e107[PMID:19413681 DOI:10.1111/j.1365-2982.2009.01310.x]
58 Han W,Wang Z,Lu X,Guo C.Protease activated receptor 4status of mast cells in post infectious irritable bowel syndrome.Neurogastroenterol Motil 2012;24:113-19,e82[PMID:22151913DOI:10.1111/j.1365-2982.2011.01841.x]
59 Kawabata A,Kawao N,Kuroda R,Tanaka A,Itoh H,Nishikawa H.Peripheral PAR-2 triggers thermal hyperalgesia and nociceptive responses in rats.Neuroreport 2001;12:715-719[PMID:11277570]
60 Coelho AM,Vergnolle N,Guiard B,Fioramonti J,Bueno L.Proteinases and proteinase-activated receptor 2:a possible role to promote visceral hyperalgesia in rats.Gastroenterology 2002;122:1035-1047[PMID:11910355]
61 Reed DE,Barajas-Lopez C,Cottrell G,Velazquez-Rocha S,Dery O,Grady EF,Bunnett NW,Vanner SJ.Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of guineapig submucosal neurons.J Physiol 2003;547:531-542[PMID:12562962 DOI:10.1113/jphysiol.2002.032011]
62 Vergnolle N,Bunnett NW,Sharkey KA,Brussee V,Compton SJ,Grady EF,Cirino G,Gerard N,Basbaum AI,Andrade-Gordon P,Hollenberg MD,Wallace JL.Proteinase-activated receptor-2 and hyperalgesia:A novel pain pathway.Nat Med 2001;7:821-826[PMID:11433347 DOI:10.1038/89945]
63 Kawabata A,Kawao N,Kitano T,Matsunami M,Satoh R,Ishiki T,Masuko T,Kanke T,Saito N.Colonic hyperalgesia triggered by proteinase-activated receptor-2 in mice:involvement of endogenous bradykinin.Neurosci Lett 2006;402:167-172[PMID:16644120DOI:10.1016/j.neulet.2006.03.074]
64 Valdez-Morales EE,Overington J,Guerrero-Alba R,Ochoa-Cortes F,Ibeakanma CO,Spreadbury I,Bunnett NW,Beyak M,Vanner SJ.Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients:a role for PAR2.Am J Gastroenterol 2013;108:1634-1643[PMID:23958521 DOI:10.1038/ajg.2013.241]
65 Wang P,Chen FX,Du C,Li CQ,Yu YB,Zuo XL,Li YQ.Increased production of BDNF in colonic epithelial cells induced by fecal supernatants from diarrheic IBS patients.Sci Rep 2015;5:10121[PMID:25998025 DOI:10.1038/srep10121]
66 Ceuleers H,Segaert E,Heirbaut J,Hanning N,Francque SM,Joossens J,De Meester I,De Man J,De Winter BY.Su1937Two Serine Protease Inhibitors,Nafamostat Mesylate and the Newly Developed SPIx,Decrease Post-Inflammatory Visceral Hypersensitivity in Rats.Gastroenterology 2016;150:S593-S4[DOI:10.1016/S0016-5085(16)32036-4]
67 Ceuleers H,De Man JG,Deiteren A,De Schepper H,Joossens J,Francque S.The effect of a potent tryptase inhibitor and a new serine protease inhibitor on visceral pain in a rat model of acute colitis.Friday,5 June 2015 08:30-10:00 Hall B2 FP-01 Sensory mechanisms.Neurogastroenterol Motility 2015;27:22-25[DOI:10.1111/nmo.12597]
68 Zhao J,Wang J,Dong L,Shi H,Wang Z,Ding H,Shi H,Lu X.A protease inhibitor against acute stress-induced visceral hypersensitivity and paracellular permeability in rats.Eur JPharmacol 2011;654:289-294[PMID:21237151 DOI:10.1016/j.ejphar.2010.12.032]
69 Zhao J,Wang Z,Zou B,Song Y,Dong L.[Camostat mesilate,a protease inhibitor,inhibits visceral sensitivity and spinal c-fos expression in rats with acute restraint stress].Nan Fang Yi Ke Da Xue Xue Bao 2014;34:1546-1550[PMID:25345960]
70 Moussa L,Bézirard V,Salvador-Cartier C,BacquiéV,Lencina C,Lévêque M,Braniste V,Ménard S,Théodorou V,Houdeau E.A low dose of fermented soy germ alleviates gut barrier injury,hyperalgesia and faecal protease activity in a rat model of inflammatory bowel disease.PLo S One 2012;7:e49547[PMID:23166707 DOI:10.1371/journal.pone.0049547]
71 Moussa L,Bézirard V,Salvador-Cartier C,BacquiéV,Houdeau E,Théodorou V.A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats.Clin Nutr 2013;32:51-58[PMID:22727545 DOI:10.1016/j.clnu.2012.05.021]
72 Bermúdez-Humarán LG,Motta JP,Aubry C,Kharrat P,RousMartin L,Sallenave JM,Deraison C,Vergnolle N,Langella P.Serine protease inhibitors protect better than IL-10 and TGF-βantiinflammatory cytokines against mouse colitis when delivered by recombinant lactococci.Microb Cell Fact 2015;14:26[PMID:25889561 DOI:10.1186/s12934-015-0198-4]
73 Mavrakanas TA,Chatzizisis YS.Bivalirudin in stable angina and acute coronary syndromes.Pharmacol Ther 2015;152:1-10[PMID:25857452 DOI:10.1016/j.pharmthera.2015.04.003]
74 Reddy P,Giugliano RP.The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.J Cardiovasc Pharmacol Ther 2014;19:526-532[PMID:24659084 DOI:10.1177/1074248414525505]
75 Mc Cormack PL.Edoxaban:a review in nonvalvular atrial fibrillation.Am J Cardiovasc Drugs 2015;15:351-361[PMID:26369340 DOI:10.1007/s40256-015-0148-x]
76 Fanola CL.Current and emerging strategies in the management of venous thromboembolism:benefit-risk assessment of dabigatran.Vasc Health Risk Manag 2015;11:271-282[PMID:26064057DOI:10.2147/VHRM.S62595]
77 Fujii K,Kanno Y,Konishi K,Ohgou N.A specific thrombin inhibitor,argatroban,alleviates herpes zoster-associated pain.JDermatol 2001;28:200-207[PMID:11449671]
78 Armstrong WB,Taylor TH,Kennedy AR,Melrose RJ,Messadi DV,Gu M,Le AD,Perloff M,Civantos F,Goodwin WJ,Wirth LJ,Kerr AR,Meyskens FL.Bowman birk inhibitor concentrate and oral leukoplakia:a randomized phase IIb trial.Cancer Prev Res(Phila)2013;6:410-418[PMID:23639862 DOI:10.1158/1940-6207.CAPR-13-0004]
79 Scully M,Gates C,Neave L.How we manage patients with heparin induced thrombocytopenia.Br J Haematol 2016;174:9-15[PMID:27097741 DOI:10.1111/bjh.14102]
80 Heinemann V,Ebert MP,Laubender RP,Bevan P,Mala C,Boeck S.Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat(WX-671)in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable,locally advanced pancreatic cancer.Br J Cancer 2013;108:766-770[PMID:23412098 DOI:10.1038/bjc.2013.62]
81 Uwagawa T,Misawa T,Tsutsui N,Ito R,Gocho T,Hirohara S,Sadaoka S,Yanaga K.Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.Am J Clin Oncol 2013;36:44-48[PMID:22157216 DOI:10.1097/COC.0b013e31823a53b2]
82 Bao P,Zhao W,Li Y,Liu Y,Zhou Y,Liu C.Protective effect of ulinastatin in patients with non-small cell lung cancer after radiation therapy:a randomized,placebo-controlled study.Med Oncol 2015;32:405[PMID:25502081 DOI:10.1007/s12032-014-0405-x]
83 Narra K,Mullins SR,Lee HO,Strzemkowski-Brun B,Magalong K,Christiansen VJ,McK ee PA,Egleston B,Cohen SJ,Weiner LM,Meropol NJ,Cheng JD.Phase II trial of single agent Val-boroP ro(Talabostat)inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.Cancer Biol Ther 2007;6:1691-1699[PMID:18032930]
84 Zhang L,Wang N,Zhou S,Ye W,Yao Q,Jing G,Zhang M.Preventive effect of ulinastatin on postoperative complications,immunosuppression,and recurrence in esophagectomy patients.World J Surg Oncol 2013;11:84[PMID:23575450 DOI:10.1186/1477-7819-11-84]
85 Krishna MT,Chauhan A,Little L,Sampson K,Hawksworth R,Mant T,Djukanovic R,Lee T,Holgate S.Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma.J Allergy Clin Immunol 2001;107:1039-1045[PMID:11398082 DOI:10.1067/mai.2001.115631]
86 Strange C,Beiko T.Treatment of Alpha-1 Antitrypsin Deficiency.Semin Respir Crit Care Med 2015;36:470-477[PMID:26238635DOI:10.1055/s-0035-1555608]
87 Twigg MS,Brockbank S,Lowry P,Fitz Gerald SP,Taggart C,Weldon S.The Role of Serine Proteases and Antiproteases in the Cystic Fibrosis Lung.Mediators Inflamm 2015;2015:293053[PMID:26185359 DOI:10.1155/2015/293053]
88 Thomas MC,Paldánius PM,Ayyagari R,Ong SH,Groop PH.Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.Diabetes Ther 2016;7:439-454[PMID:27502495 DOI:10.1007/s13300-016-0189-4]
89 Royston D.The current place of aprotinin in the management of bleeding.Anaesthesia 2015;70 Suppl 1:46-9,e17[PMID:25440394 DOI:10.1111/anae.12907]
90 Ono S,Aosasa S,Mochizuki H.Effects of a protease inhibitor on reduction of surgical stress in esophagectomy.Am J Surg 1999;177:78-82[PMID:10037314]
91 Inagaki H,Nonami T,Kurokawa T,Takeuchi Y,Okuda N,Nakao A,Sakamoto J.Effects of nafamostat mesilate,a synthetic protease inhibitor,on immunity and coagulation after hepatic resection.Hepatogastroenterology 1999;46:3223-3228[PMID:10626190]
92 Ito H,Nakayama H,Yokose T,Yamada K.Prophylaxis for acute exacerbation of interstitial pneumonia after lung resection.Asian Cardiovasc Thorac Ann 2014;22:948-954[PMID:24585320 DOI:10.1177/0218492314526187]
93 Joossens J,Ali OM,El-Sayed I,Surpateanu G,Van der Veken P,Lambeir AM,Setyono-Han B,Foekens JA,Schneider A,Schmalix W,Haemers A,Augustyns K.Small,potent,and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties.J Med Chem 2007;50:6638-6646[PMID:18052026 DOI:10.1021/jm700962j]